RS61374B1 - Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti - Google Patents

Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti

Info

Publication number: RS61374B1
Authority: RS; Serbia
Prior art keywords: antibodies; functional fragments; tnf alpha; tnf; alpha
Prior art date: 2016-03-17

Application number

RS20210112A

Other languages

English (en)

Inventor

Tea Gunde

Sebastian Meyer

Esther Maria Furrer

Original Assignee

Tillotts Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-17

Filing date

2016-03-17

Publication date

2021-02-26

2016-03-17 Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag

2021-02-26 Publication of RS61374B1 publication Critical patent/RS61374B1/sr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

RS20210112A 2016-03-17 2016-03-17 Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti RS61374B1 (sr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16160907.8A EP3219726B1 (en)	2016-03-17	2016-03-17	Anti-tnf alpha-antibodies and functional fragments thereof

Publications (1)

Publication Number	Publication Date
RS61374B1 true RS61374B1 (sr)	2021-02-26

Family

ID=55542576

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RS20210112A RS61374B1 (sr)	2016-03-17	2016-03-17	Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
RS20231087A RS64830B1 (sr)	2016-03-17	2017-03-16	Anti-tnf-alfa antitela i njihovi funkcionalni fragmenti

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
RS20231087A RS64830B1 (sr)	2016-03-17	2017-03-16	Anti-tnf-alfa antitela i njihovi funkcionalni fragmenti

Country Status (39)

Country	Link
US (3)	US11459383B2 (sr)
EP (3)	EP3219726B1 (sr)
JP (2)	JP7129398B2 (sr)
KR (2)	KR102470235B1 (sr)
CN (1)	CN109071650B (sr)
AR (1)	AR107917A1 (sr)
AU (1)	AU2017235387A1 (sr)
BR (1)	BR112018016667A2 (sr)
CA (1)	CA3011784C (sr)
CL (1)	CL2018002649A1 (sr)
CO (1)	CO2018009783A2 (sr)
CR (1)	CR20180448A (sr)
CY (1)	CY1123784T1 (sr)
DK (2)	DK3219726T3 (sr)
EA (1)	EA039760B1 (sr)
ES (2)	ES2836349T3 (sr)
FI (1)	FI3430043T3 (sr)
GE (1)	GEP20217307B (sr)
HR (2)	HRP20231464T1 (sr)
HU (2)	HUE052773T2 (sr)
IL (1)	IL261031A (sr)
JO (2)	JOP20170064B1 (sr)
LT (2)	LT3219726T (sr)
MA (1)	MA43717B1 (sr)
MD (1)	MD3430043T2 (sr)
MX (1)	MX2018011258A (sr)
MY (1)	MY194041A (sr)
PH (1)	PH12018501907A1 (sr)
PL (2)	PL3219726T3 (sr)
PT (2)	PT3219726T (sr)
RS (2)	RS61374B1 (sr)
SA (1)	SA518400027B1 (sr)
SG (1)	SG11201807062RA (sr)
SI (2)	SI3219726T1 (sr)
TN (1)	TN2018000298A1 (sr)
TW (2)	TWI784945B (sr)
UY (1)	UY37157A (sr)
WO (1)	WO2017158092A1 (sr)
ZA (4)	ZA202108599B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108884156B (zh)	2016-03-17	2021-10-01	努玛创新有限公司	抗TNFα抗体及其功能片段
PT3219727T (pt)	2016-03-17	2021-01-21	Tillotts Pharma Ag	Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
EP3430042B1 (en)	2016-03-17	2023-05-24	Numab Innovation AG	Anti-tnfalpha-antibodies and functional fragments thereof
EP3456737B1 (en) *	2017-09-19	2024-02-14	Tillotts Pharma Ag	Antibody variants
EP3456736B1 (en) *	2017-09-19	2021-04-07	Tillotts Pharma Ag	Antibody variants
EP3456738A1 (en) *	2017-09-19	2019-03-20	Tillotts Pharma Ag	Antibody variants
WO2020114616A1 (en)	2018-12-07	2020-06-11	Tillotts Pharma Ag	Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
WO1991010741A1 (en)	1990-01-12	1991-07-25	Cell Genesys, Inc.	Generation of xenogeneic antibodies
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es)	1990-08-29	1997-12-16	Genpharm Int	Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
US5919452A (en)	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
DE69233482T2 (de)	1991-05-17	2006-01-12	Merck & Co., Inc.	Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es)	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es)	1991-12-02	2005-04-01	Medical Research Council	Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
NO309690B1 (no)	1995-01-23	2001-03-12	Western Atlas Int Inc	Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
CA2219361C (en)	1995-04-27	2012-02-28	Abgenix, Inc.	Human antibodies derived from immunized xenomice
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
SI9720020B (en) *	1996-02-09	2001-12-31	Basf Ag	Human antibodies that bind human TNF alpha
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
EP1500329B1 (en)	1996-12-03	2012-03-21	Amgen Fremont Inc.	Human antibodies that specifically bind human TNF alpha
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
CN100387621C (zh)	1997-04-14	2008-05-14	麦可麦脱股份公司	抗人抗原受体的新的生产方法及其用途
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
ES2301254T3 (es)	1998-11-18	2008-06-16	Genentech, Inc.	Variantes de anticuerpos con una afinidad de union mayor en comparacion con los anticuerpos parentales.
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US7431927B2 (en)	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
NZ563580A (en)	2005-06-07	2010-09-30	Esbatech An Alcon Biomedical R	Stable and soluble antibodies inhibiting TNFaplha
KR101882352B1 (ko)	2008-06-25	2018-07-26	에스바테크 - 어 노바티스 컴파니 엘엘씨	보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
KR20190133077A (ko)	2008-06-25	2019-11-29	에스바테크 - 어 노바티스 컴파니 엘엘씨	ＴＮＦα를 저해하는 안정한 가용성 항체
CN102088958A (zh)	2008-07-10	2011-06-08	艾斯巴技术,爱尔康生物医药研究装置有限责任公司	用于大分子的增强的递送的方法和组合物
KR20150038556A (ko) *	2010-04-07	2015-04-08	애브비 인코포레이티드	ＴＮＦ-α 결합 단백질
CA2805572A1 (en)	2010-07-16	2012-01-19	Martin Hegen	Modified single domain antigen binding molecules and uses thereof
KR20130062366A (ko)	2010-09-30	2013-06-12	쳉두 캉홍 바이오테크놀로지스 코. 리미티드	인간화 항 TNF α 항체 및 그의 항원 결합 단편 (FAB) 및 용도
IL293477A (en)	2013-06-26	2022-08-01	Numab Therapeutics AG	New frameworks for antibodies
US9416197B2 (en) *	2013-11-01	2016-08-16	Ibc Pharmaceuticals, Inc.	Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
MX2016012479A (es) *	2014-03-26	2017-05-23	Cell Medica Switzerland Ag	Miembros de unión al factor de necrosis tumoral (tnf) alfa.
CN108884156B (zh)	2016-03-17	2021-10-01	努玛创新有限公司	抗TNFα抗体及其功能片段
PT3219727T (pt)	2016-03-17	2021-01-21	Tillotts Pharma Ag	Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
EP3430042B1 (en)	2016-03-17	2023-05-24	Numab Innovation AG	Anti-tnfalpha-antibodies and functional fragments thereof

2016
- 2016-03-17 SI SI201631040T patent/SI3219726T1/sl unknown
- 2016-03-17 EP EP16160907.8A patent/EP3219726B1/en active Active
- 2016-03-17 RS RS20210112A patent/RS61374B1/sr unknown
- 2016-03-17 ES ES16160907T patent/ES2836349T3/es active Active
- 2016-03-17 PT PT161609078T patent/PT3219726T/pt unknown
- 2016-03-17 LT LTEP16160907.8T patent/LT3219726T/lt unknown
- 2016-03-17 PL PL16160907T patent/PL3219726T3/pl unknown
- 2016-03-17 DK DK16160907.8T patent/DK3219726T3/da active
- 2016-03-17 HU HUE16160907A patent/HUE052773T2/hu unknown
2017
- 2017-03-16 KR KR1020187022632A patent/KR102470235B1/ko active IP Right Grant
- 2017-03-16 KR KR1020227040533A patent/KR20220158877A/ko not_active Application Discontinuation
- 2017-03-16 JO JOP/2017/0064A patent/JOP20170064B1/ar active
- 2017-03-16 TN TNP/2018/000298A patent/TN2018000298A1/en unknown
- 2017-03-16 CN CN201780015298.5A patent/CN109071650B/zh active Active
- 2017-03-16 DK DK17710748.9T patent/DK3430043T3/da active
- 2017-03-16 JP JP2019500013A patent/JP7129398B2/ja active Active
- 2017-03-16 HR HRP20231464TT patent/HRP20231464T1/hr unknown
- 2017-03-16 GE GEAP201714876A patent/GEP20217307B/en unknown
- 2017-03-16 PT PT177107489T patent/PT3430043T/pt unknown
- 2017-03-16 SI SI201731446T patent/SI3430043T1/sl unknown
- 2017-03-16 EP EP17710748.9A patent/EP3430043B1/en active Active
- 2017-03-16 MD MDE20190099T patent/MD3430043T2/ro unknown
- 2017-03-16 US US16/085,506 patent/US11459383B2/en active Active
- 2017-03-16 CA CA3011784A patent/CA3011784C/en active Active
- 2017-03-16 SG SG11201807062RA patent/SG11201807062RA/en unknown
- 2017-03-16 MA MA43717A patent/MA43717B1/fr unknown
- 2017-03-16 RS RS20231087A patent/RS64830B1/sr unknown
- 2017-03-16 AU AU2017235387A patent/AU2017235387A1/en active Pending
- 2017-03-16 MX MX2018011258A patent/MX2018011258A/es unknown
- 2017-03-16 FI FIEP17710748.9T patent/FI3430043T3/fi active
- 2017-03-16 EP EP23192170.1A patent/EP4275745A3/en active Pending
- 2017-03-16 PL PL17710748.9T patent/PL3430043T3/pl unknown
- 2017-03-16 HU HUE17710748A patent/HUE064238T2/hu unknown
- 2017-03-16 CR CR20180448A patent/CR20180448A/es unknown
- 2017-03-16 ES ES17710748T patent/ES2963221T3/es active Active
- 2017-03-16 LT LTEPPCT/EP2017/056237T patent/LT3430043T/lt unknown
- 2017-03-16 BR BR112018016667A patent/BR112018016667A2/pt unknown
- 2017-03-16 MY MYPI2018001566A patent/MY194041A/en unknown
- 2017-03-16 WO PCT/EP2017/056237 patent/WO2017158092A1/en active Application Filing
- 2017-03-16 EA EA201891788A patent/EA039760B1/ru unknown
- 2017-03-17 TW TW106108832A patent/TWI784945B/zh active
- 2017-03-17 AR ARP170100675A patent/AR107917A1/es unknown
- 2017-03-17 TW TW111145252A patent/TWI829444B/zh active
- 2017-03-17 UY UY0001037157A patent/UY37157A/es not_active Application Discontinuation
2018
- 2018-08-07 IL IL261031A patent/IL261031A/en unknown
- 2018-09-06 PH PH12018501907A patent/PH12018501907A1/en unknown
- 2018-09-14 CL CL2018002649A patent/CL2018002649A1/es unknown
- 2018-09-16 SA SA518400027A patent/SA518400027B1/ar unknown
- 2018-09-17 CO CONC2018/0009783A patent/CO2018009783A2/es unknown
2021
- 2021-01-13 CY CY20211100021T patent/CY1123784T1/el unknown
- 2021-01-22 HR HRP20210123TT patent/HRP20210123T1/hr unknown
- 2021-04-22 JO JOP/2021/0085A patent/JOP20210085A1/ar unknown
- 2021-11-04 ZA ZA2021/08599A patent/ZA202108599B/en unknown
- 2021-11-04 ZA ZA2021/08600A patent/ZA202108600B/en unknown
- 2021-11-04 ZA ZA2021/08601A patent/ZA202108601B/en unknown
- 2021-11-04 ZA ZA2021/08602A patent/ZA202108602B/en unknown
2022
- 2022-06-06 JP JP2022091271A patent/JP2022130407A/ja active Pending
- 2022-08-18 US US17/890,857 patent/US20230272059A1/en active Pending
- 2022-10-03 US US17/958,759 patent/US20230279091A1/en active Pending

Also Published As

Publication number	Publication date
HUE064238T2 (hu)	2024-02-28
JP2019512268A (ja)	2019-05-16
HRP20231464T1 (hr)	2024-03-01
US20210198353A1 (en)	2021-07-01
EP3219726B1 (en)	2020-12-02
ZA202108600B (en)	2022-03-30
KR102470235B1 (ko)	2022-11-24
JOP20170064B1 (ar)	2021-08-17
EP4275745A2 (en)	2023-11-15
KR20180120149A (ko)	2018-11-05
SI3430043T1 (sl)	2024-01-31
TW201739766A (zh)	2017-11-16
CN109071650B (zh)	2022-05-13
ES2836349T3 (es)	2021-06-24
AR107917A1 (es)	2018-06-28
CN109071650A (zh)	2018-12-21
BR112018016667A2 (pt)	2019-02-05
EP3430043B1 (en)	2023-08-30
TWI784945B (zh)	2022-12-01
PH12018501907A1 (en)	2019-06-17
CA3011784A1 (en)	2017-09-21
WO2017158092A1 (en)	2017-09-21
ZA202108601B (en)	2022-03-30
LT3430043T (lt)	2023-12-27
LT3219726T (lt)	2021-01-25
JP7129398B2 (ja)	2022-09-01
MX2018011258A (es)	2019-02-13
RS64830B1 (sr)	2023-12-29
IL261031A (en)	2018-10-31
KR20220158877A (ko)	2022-12-01
CR20180448A (es)	2019-01-25
MA43717B1 (fr)	2023-11-30
PL3430043T3 (pl)	2024-03-11
PT3219726T (pt)	2020-12-15
EA201891788A1 (ru)	2019-01-31
US20230272059A1 (en)	2023-08-31
MA43717A (fr)	2018-11-28
HRP20210123T1 (hr)	2021-03-05
US20230279091A1 (en)	2023-09-07
JP2022130407A (ja)	2022-09-06
CL2018002649A1 (es)	2018-11-09
MD3430043T2 (ro)	2024-02-29
EP3219726A1 (en)	2017-09-20
SG11201807062RA (en)	2018-09-27
HUE052773T2 (hu)	2021-05-28
MY194041A (en)	2022-11-09
SA518400027B1 (ar)	2022-03-06
US11459383B2 (en)	2022-10-04
EP4275745A3 (en)	2023-12-20
TN2018000298A1 (en)	2020-01-16
ES2963221T3 (es)	2024-03-26
AU2017235387A1 (en)	2018-09-27
ZA202108602B (en)	2022-03-30
EA039760B1 (ru)	2022-03-10
GEP20217307B (en)	2021-10-25
DK3219726T3 (da)	2020-12-07
JOP20210085A1 (ar)	2023-01-30
PL3219726T3 (pl)	2021-07-19
CA3011784C (en)	2024-04-23
TWI829444B (zh)	2024-01-11
CY1123784T1 (el)	2022-05-27
SI3219726T1 (sl)	2021-02-26
TW202311288A (zh)	2023-03-16
FI3430043T3 (fi)	2023-11-17
DK3430043T3 (da)	2023-11-27
EP3430043A1 (en)	2019-01-23
ZA202108599B (en)	2022-03-30
CO2018009783A2 (es)	2018-09-28
PT3430043T (pt)	2023-11-23
UY37157A (es)	2017-10-31

Publication	Publication Date	Title
IL283321A (en)	2021-07-29	Antibodies against muc16 and their uses
HK1254953A1 (zh)	2019-08-02	抗vista抗體和片段
HK1254861A1 (zh)	2019-07-26	抗lag3抗體及其用途
HK1252615A1 (zh)	2019-05-31	Il-8-結合抗體及其應用
HK1250238A1 (zh)	2018-12-07	抗angptl8抗體及其用途
HK1256381A1 (zh)	2019-09-20	抗pacap抗體及其用途
IL261140A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
ZA202108599B (en)	2022-03-30	Anti-tnfalpha-antibodies and functional fragments thereof
GB201503387D0 (en)	2015-04-15	Anti-carbapenem antibodies and uses thereof
IL261261A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
IL261098A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
IL261793A (en)	2018-10-31	Anti-tnfalpha antibodies and their functional parts
HK1254240A1 (zh)	2019-07-12	抗羥腐胺賴氨酸抗體及其用途
AU2017235061A1 (en)	2017-09-21	Anti-TNFalpha-antibodies and functional fragments thereof